Celebrex, Bextra Face FDA Scrutiny This Week
FDA Practices May Also Face Debate, Official Says
FDA officials say that this week's hearings are likely to go beyond Cox-2
drugs to broader issues of how the agency polices the safety of drugs already
on the market, FDA officials say. The FDA has also faced questions over how it
handled growing evidence that last year led to stricter warnings on an
increased risk of suicidal behavior in children who take antidepressants.
In an interview in late January, acting FDA Commissioner Lester M. Crawford
said the agency would also look to experts for cues on how to approach
improving safety reviews in general.
President Bush on Monday nominated Crawford to become the FDA's permanent
commissioner, the White House announced. The post has been vacant for more than
With reporting by Salynn Boyles.